8-K: Axogen Announces CFO Transition and Reports Q1 2025 Financial Results

Axogen reports a 17.4% increase in first quarter revenue and announces Lindsey Hartley as the new CFO, succeeding Nir Naor.

Summary

• Axogen, Inc. reported its first quarter 2025 financial results, showing a revenue increase of 17.4% to $48.6 million compared to the first quarter of 2024.
• The gross margin for the quarter was 71.9%, a decrease from 78.8% in the same period last year.
• The net loss was $3.8 million, or $0.08 per share, an improvement from the $6.6 million loss, or $0.15 per share, in the first quarter of 2024.
• Adjusted EBITDA for the quarter was $2.9 million, up from $1.0 million in the first quarter of 2024.
• The company's cash and investments totaled $28.1 million as of March 31, 2025, down from $39.5 million at the end of 2024.
• Axogen is maintaining its full-year revenue growth guidance of 15% to 17% and expects a gross margin in the range of 73% to 75%.
• Lindsey Hartley was appointed as the new Chief Financial Officer, effective May 12, 2025, succeeding Nir Naor, who will remain in an advisory role until July 1, 2025.
• The FDA accepted the filing of the company's BLA for Avance Nerve Graft with a goal date of September 5, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, improved profitability, and the anticipated approval of a key product. However, the decrease in gross margin and cash reserves tempers the overall outlook.

Positives

• Revenue increased by 17.4% compared to the first quarter of 2024, indicating strong sales performance.
• The net loss decreased from $6.6 million to $3.8 million, showing improved profitability.
• Adjusted EBITDA increased significantly, suggesting better operational efficiency.
• The FDA accepted the BLA filing for Avance Nerve Graft, with a target approval date in September 2025.
• The company is maintaining its full-year revenue growth guidance.

Negatives

• Gross margin decreased from 78.8% to 71.9% due to increased product costs and inventory write-offs.
• Cash and investments decreased from $39.5 million to $28.1 million.

Risks

• Potential disruptions from leadership transitions could impact business operations.
• Global supply chain issues and record inflation may affect product costs and profitability.
• Hospital staffing challenges could limit the adoption of Axogen's products.
• Regulatory processes and approvals may face unexpected delays or rejections.
• Global business disruption from geopolitical conflicts and escalating trade disputes could impact financial performance.

Future Outlook

Axogen maintains its full-year revenue growth guidance in the range of 15% to 17% and expects gross margin to be in the range of 73% to 75%. The company also expects to be net cash flow positive for the full year.

Management Comments

• Michael Dale, CEO, stated that the company's revenue growth remains robust and that market development objectives and business model optimization plans remain the right priorities.
• Lindsey Hartley expressed her excitement to step into the CFO role and focus on financial discipline and strategic growth initiatives.

Industry Context

Axogen operates in the peripheral nerve repair market, which is driven by traumatic injuries and surgical procedures. The company's focus on innovative, clinically proven, and economically effective repair solutions positions it as a leader in this space.

Comparison to Industry Standards

• Integra LifeSciences, Stryker, and Baxter International are competitors in the broader regenerative medicine and surgical solutions market.
• Axogen's revenue growth of 17.4% in Q1 2025 indicates a strong performance compared to the average growth rates of its competitors.
• The anticipated approval of Avance Nerve Graft could further solidify Axogen's market position and provide a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and improved profitability.
• Employees: Positive impact due to the promotion of Lindsey Hartley and the company's growth prospects.
• Customers: Positive impact due to the potential approval of Avance Nerve Graft, which could improve treatment options.
• Suppliers: Stable relationships expected due to the company's continued growth.

Next Steps

• Axogen anticipates FDA approval of the Avance Nerve Graft BLA by September 5, 2025.
• The company will focus on financial discipline and strategic growth initiatives under the new CFO, Lindsey Hartley.

Key Dates

Keywords

Axogen, financial results, CFO, Lindsey Hartley, Nir Naor, revenue, EBITDA, Avance Nerve Graft, BLA, FDA, peripheral nerve repair